Gilead Sciences Inc (GILD) Financials
Key financial figures for Gilead Sciences Inc (Q3 2026).
Gilead's Q3 2026 product sales rose 13% to $8.3 billion, led by HIV up 18% to $6.2 billion, and management raised its full-year product sales guidance to $31.0 billion to $31.3 billion. Total product sales rose 13% to $8,289 million and product sales excluding Veklury rose 16% to $8,203 million; total revenues rose 7% to $8,300 million as royalty, contract and other revenues fell to $11 million from $424 million, which included a prior-year intellectual property sale. HIV product sales rose 18% to $6,249 million. Biktarvy rose 10% to $4,059 million, Descovy rose 49% to $1,046 million and Yeztugo reached $305 million, from $39 million a year earlier. On the outlook: For full year 2026 Gilead now expects product sales of $31,000 million to $31,300 million (previously $30,100 million to $30,400 million), product sales excluding Veklury of $30,700 million to $31,000 million (previously $29,800 million to $30,100 million), Veklury of about $300 million (unchanged), a GAAP diluted loss per share of $(4.40) to $(4.05) (previously $(3.75) to $(3.40)) and a non-GAAP diluted loss per share of $(1.20) to $(0.85) (previously $(0.65) to $(0.30)); the EPS guidance includes about $9.88 per share from acquired IPR&D charges of $12.4 billion related to the Arcellx, Tubulis, Ouro Medicines and PepStar transactions, net of the Lakefront collaboration and related taxes. Figures are for Q3 2026, as Gilead Sciences, Inc. reported them.
- Revenue
- $8.3B
- Net Income
- $2.4B
- EPS
- $1.96
- Total Assets
- $51.4B
- Operating Cash Flow
- $5.0B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $8.3B | $2.4B | $1.94 | 41.71% | $4.8B |
| Q2 FY2026 | $7.8B | -$10.5B | -$8.45 | -133.21% | |
| Q1 FY2026 | $7.0B | $2.0B | $1.61 | 37.16% | $2.4B |
| Q4 FY2025 | $7.9B | $2.2B | $1.74 | 25.04% | $3.1B |
| Q3 FY2025 | $7.8B | $3.1B | $2.43 | 42.82% | $4.0B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $29.4B | $8.5B | $6.78 | 39.74% | $9.5B |
| FY2024 | $28.8B | $480M | $0.38 | 5.78% | $10.3B |
| FY2023 | $27.1B | $5.7B | $4.50 | 28.05% | $7.4B |
Frequently asked questions
What was Gilead Sciences, Inc.'s revenue last quarter?
Gilead Sciences, Inc. reported revenue of $8.30 billion for Q3 FY2026, up 6.8% from the same period a year earlier.
Is Gilead Sciences, Inc. profitable?
Yes. Gilead Sciences, Inc. reported net income of $2.43 billion for Q3 FY2026, a net margin of 29.27% on revenue.
How has Gilead Sciences, Inc.'s margin trended?
Operating margin was 41.71% in Q3 FY2026, compared with 42.82% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Gilead Sciences, Inc. generate?
Gilead Sciences, Inc. generated free cash flow of $4.80 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Gilead Sciences Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.